The Technical Analyst
Atossa Therapeutics Inc [ATOS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Atossa Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.19% $1.420
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 177.93 mill |
| EPS: | -0.240 |
| P/E: | -5.92 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 125.30 mill |
| Avg Daily Volume: | 1.583 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.92 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.01x |
| Company: PE -5.92 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.702 (-50.53%) $-0.718 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.280 - 1.560 ( +/- 9.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-10 | Finn Jonathan | Buy | 25 000 | Common Stock |
| 2024-03-09 | Cigler Tessa | Buy | 20 834 | Stock Option (right to buy) |
| 2024-03-09 | Cigler Tessa | Buy | 0 | |
| 2023-11-15 | Weaver Gregory L | Sell | 50 000 | Common Stock |
| 2023-11-15 | Finn Jonathan | Buy | 62 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 71.70 |
| Last 98 transactions |
| Buy: 26 594 652 | Sell: 4 017 362 |
Forecast:
16:00 - $1.410
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.410
Forecast 2: 16:00 - $1.410
Forecast 3: 16:00 - $1.410
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.420 (5.19% ) |
| Volume | 2.32 mill |
| Avg. Vol. | 1.583 mill |
| % of Avg. Vol | 146.36 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATOS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Last 10 Buy Signals
Latest Press Releases
2024-04-15 08:30:00 - Press Release
Atossa Therapeutics And Quantum Leap Healthcare Announce I-spy 2 Clinical Trial To Evaluate (z)-endoxifen In Combination With Abemaciclib (verzenio®) In Women With Er+/her2- Breast Cancer
Seattle, april 15, 2024 (globe newswire) -- atossa therapeutics, inc. (nasdaq: atos) (“atossa” or the “company”) and quantum leap healthcare collaborative™ today announced the initiation of a new study to evaluate atossa's proprietary (z)-endoxifen in combination with abemaciclib (verzenio®), a cyclin-dependent kinase (cdk) 4/6 inhibitor marketed by eli lilly and company, in women with er+/her2- breast cancer. atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
2024-04-11 08:30:00 - Press Release
Atossa To Participate In Noble Capital Markets Emerging Growth Healthcare Conference
Seattle, april 11, 2024 (globe newswire) -- atossa therapeutics, inc. (nasdaq: atos) (“atossa” or the “company”) today announced that chief executive officer steven quay, m.d., ph.d., will speak at the noble capital markets emerging growth healthcare conference on wednesday, april 17 at 9:00 am et. the presentation will be available virtually and members of the company's leadership team will be available for one-on-one meetings with registered investors of the conference. atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
2024-04-09 11:59:00 - Press Release
Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 Evangeline Clinical Trial Showing 100% Disease Control Rate After 24-weeks Of Treatment With (z)-endoxifen
Seattle, april 09, 2024 (globe newswire) -- atossa therapeutics, inc. (nasdaq: atos) (“atossa” or the “company”) today announced promising safety and efficacy data from the company's phase 2 evangeline (endoxifen versus exemestane goserelin) clinical trial. the evangeline study is evaluating (z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with grade 1 or 2 estrogen receptor positive (er+) / human epidermal growth factor receptor 2 negative (her2-) breast cancer. atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
2024-04-01 16:00:00 - Press Release
Atossa Therapeutics Announces Year-end 2023 Financial Results And Provides Corporate Update
Seattle, april 01, 2024 (globe newswire) -- atossa therapeutics, inc. (nasdaq: atos) (“atossa” or the “company”), today announced financial results for the fourth quarter and full year ended december 31, 2023, and provided an update on recent company developments. atossa is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer and other breast conditions.
2024-03-19 08:30:00 - Press Release
Atossa Therapeutics Provides Five-year (z)-endoxifen Treatment Update On Fda-approved "expanded Access" Program For A U.s. Breast Cancer Patient
Seattle, march 19, 2024 (globe newswire) -- atossa therapeutics, inc. (nasdaq: atos) (“atossa” or the “company”), today announced that the pre-menopausal, estrogen receptor positive (er+) / human epidermal growth factor receptor 2 negative (her2-), breast cancer patient who received neoadjuvant and adjuvant (z)-endoxifen therapy under an fda-approved "expanded access" program has completed five years of treatment. as of the date of this press release, the patient remains cancer-free and has reported no significant safety or tolerability issues over the course of her treatment. atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Latest News
2024-04-15 09:22:21 - Proactive Investors
Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drug
Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating Atossa's lead drug candidate (Z)-endoxifen in combination with Eli Lilly and Co (NYSE:LLY)'s abemaciclib (VERZENIO) in women with Estrogen Receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The clinical-stage biopharmaceutical company said the new study arm would enroll approximately 20 women newly diagnosed with ER+/HER2- invasive breast cancer.
2024-04-11 11:11:05 - Zacks Investment Research
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
2024-04-09 13:02:15 - Proactive Investors
Atossa Therapeutics reports positive data from breast cancer treatment trial
Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled encouraging safety and efficacy findings from its Phase 2 EVANGELINE clinical trial evaluating (Z)-endoxifen as a neoadjuvant therapy for breast cancer. Data presented at the American Association for Cancer Research (AACR) Annual Meeting showed that six out of seven individuals displayed Ki-67 levels below 10%, indicating favorable responses to treatment.
2024-04-01 16:28:49 - Proactive Investors
Atossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestones
Atossa Therapeutics Inc (NASDAQ:ATOS) told investors it ended 2023 with $88.5 million in cash and cash equivalents and no debt as it advanced its investigational therapeutic (Z)-endoxifen, which is targeting breast cancer and other breast conditions. For the year ended December 31, 2023, Atossa spent $17.3 million on research and development, including spending on clinical and non-clinical trials and drug development costs for (Z)-endoxifen.
2024-03-20 11:51:38 - Proactive Investors
Atossa Therapeutics' breast cancer drug milestone sparks investor enthusiasm
Atossa Therapeutics Inc (NASDAQ:ATOS) shares continued to move higher on Wednesday, buoyed by the news that a patient with pre-menopausal breast cancer had successfully completed a five-year treatment using its investigative breast cancer therapy (Z)-endoxifen. Shares of the biotechnology company added 5% at $1.63 late morning Wednesday.
2024-03-19 09:16:09 - Proactive Investors
Atossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifen
Atossa Therapeutics Inc (NASDAQ:ATOS), a company specializing in developing pharmaceuticals, has announced that a pre-menopausal breast cancer patient has completed a successful five-year treatment using its drug (Z)-endoxifen. The Seattle-based company reported that the patient, diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer, remains cancer-free with no significant safety or tolerability issues reported throughout the treatment period.
2024-03-12 09:53:00 - Proactive Investors
Atossa Therapeutics adds breast cancer expert to board
Atossa Therapeutics Inc (NASDAQ:ATOS), the biopharmaceutical company, has appointed Tessa Cigler, the breast cancer specialist, to its board of directors, effective immediately. Cigler works as a medical oncologist and clinical investigator at New York's Weill Cornell Breast Center, dealing with breast cancer patients daily.
2024-03-06 09:24:53 - Proactive Investors
Atossa Therapeutics to present data from ongoing Phase 2 breast cancer trial
Atossa Therapeutics Inc (NASDAQ:ATOS) announced it will present data from the 40mg pharmacokinetic run-in cohort of its ongoing Phase 2 EVANGELINE study at the American Association for Cancer Research Annual Meeting being held in San Diego, California, from April 5 to 10. The EVANGELINE study is evaluating Atossa's lead asset (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with estrogen receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.
2024-02-22 09:56:01 - Proactive Investors
Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trial
Atossa Therapeutics Inc (NASDAQ:ATOS) announced that the first patient has been dosed with its proprietary selected estrogen receptor modulator (Z)-endoxifen in its Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS) Phase 2 study. DCIS is considered the earliest form of breast cancer, usually found during breast cancer screening.
2024-02-12 11:49:53 - Proactive Investors
Atossa Therapeutics' ‘standalone and superior drug' Z-endoxifen for breast cancer seen boosting shares by 300%
Atossa Therapeutics Inc (NASDAQ:ATOS) shares have a 300% upside on the strength of the clinical-stage biopharmaceutical company's lead asset Z-endoxifen as a potential breast cancer treatment, according to analysts at H.C. Wainwright & Co.